NCT05429463View on ClinicalTrials.gov

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

PHASE3RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

November 11, 2025

Study Completion Date

November 11, 2029

Conditions
Squamous Cell Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

Sintilimab

200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

DRUG

Carboplatin

AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.

DRUG

Albumin-Bound Paclitaxel

260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

Trial Locations (1)

310009

RECRUITING

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER